CBIO
Crescent Biopharma, Inc.
$17.09
+0.01 (+0.06%)
At close · Jul 2
Market Cap
$471.25M
Shares
27,571,935
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.09
Open$17.00
Day$16.50–17.92
52W$8.72–27.41
Avg vol 30d308K
Short int3.3M · 12.1% float · 15.8d
Short vol58%
Last earningsApr 29, 2026
DataJan 2020–Jul 2026
Filing10-Q · Apr 29
Equibles Rating
blended score · not investment advice
Overall
Sell
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+18% above
−
Price vs 50-day avg
−12% below
◦
RSI (14)
43 · neutral
−
MACD trend
negative
◦
52-week position
45% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $19 › 200d $14 — 50d above 200d
+
Institutional flow
+7% holders QoQ · +17 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
12.14% of float · ▲ +2.7% MoM · 15.8 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
60 holders — near 1-yr high, broad support
Fundamentals
Weak
−
Revenue growth
−100% Y/Y
−
EPS growth
−2% Y/Y
−
Free cash flow
$-72.5M
+
Balance sheet
net cash $213.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Jul 18, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 29, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+18% above
Bullish
Price vs 50-day avg
−12% below
Bearish
RSI (14)
43 · neutral
Neutral
MACD trend
negative
Bearish
52-week position
45% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $19 › 200d $14 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.14% of float · ▲ +2.7% MoM · 15.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
60 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $9
Now $17 · 45%
52-wk high $27
vs 200-day avg +18%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CBIO
this stock
Crescent Biopharma, Inc.
|
$471.25M | +44.1% | -99.9% | — | 12.1% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CBIO | +0.6% | -5.0% | +55.8% | -5.1% | +44.1% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -0.8% | -3.7% | +47.8% | -4.8% | +34.9% |